Efficacy of Tiopronin in treatment of severe non-alcoholic fatty liver disease

Eur Rev Med Pharmacol Sci. 2014;18(2):160-4.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome of which the main feature is diffuse macrovesicular hepatic steatosis caused by deposition of excessive free fatty acid and triglyceride in liver parenchyma.

Aim: To observe the efficacy of Tiopronin in treatment of severe nonalcoholic fatty liver disease (NAFLD).

Patients and methods: 30 patients with severe NAFLD were treated with Tiopronin for 3 months. 30 healthy people were selected as control. The body mass index (BMI) and plasma levels of endotoxin (ET), leptin, IL-6 and IL-8 were measured before and after treatment.

Results: The serum levels of ET, leptin, IL-6 and IL-8 in severe NAFLD group were significantly higher than those in control group (p < 0.05). After treatment with Tiopronin, these indexes were significantly lower than before (p < 0.05).

Conclusions: The intestinal endotoxemia (IETM) occurs in patients with severe NAFLD. Leptin, IL-6 and IL-8 play important roles in pathogenesis of NAFLD. Tiopronin can reduce the levels of ET, leptin, IL-6 and IL-8 for treatment of NAFLD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Body Mass Index
  • Endotoxins / blood
  • Female
  • Humans
  • Interleukin-6 / blood
  • Interleukin-8 / blood
  • Leptin / blood
  • Male
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Tiopronin / therapeutic use*
  • Triglycerides / blood

Substances

  • Endotoxins
  • Interleukin-6
  • Interleukin-8
  • Leptin
  • Triglycerides
  • Tiopronin